B. Metzler seel. Sohn & Co. AG Purchases New Position in Gilead Sciences, Inc. $GILD

Key Points

• B. Metzler seel. Sohn & Co. acquired 114,360 Gilead shares worth approximately $14.4 million in the second quarter. Institutional investors now own 83.67% of the company.
• Gilead reported quarterly revenue of $7.80 billion, exceeding expectations, while revenue rose 10.6% year over year; the company also declared a $0.82 quarterly dividend, yielding about 2.3% annually.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and $158.04 target price, although recent insider sales and mixed long-term earnings revisions introduce some caution.

B. Metzler seel. Sohn & Co. AG acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 114,360 shares of the biopharmaceutical company's stock, valued at approximately $14,448,000.

Several other large investors have also recently bought and sold shares of GILD. BlackRock Inc. bought a new position in shares of Gilead Sciences during the second quarter worth $15,393,785,000. Norges Bank acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $2,617,152,000. Deutsche Bank AG bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at $918,387,000. Boston Partners bought a new stake in shares of Gilead Sciences in the 4th quarter valued at $517,808,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Gilead Sciences during the 2nd quarter worth $398,905,000. Institutional investors own 83.67% of the company's stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead’s collaboration with Nucleai highlights a potential strategic shift toward data-driven oncology. Nucleai’s spatial-biology and artificial-intelligence capabilities could help Gilead identify biomarkers, improve patient selection and support its cancer-drug pipeline, although the financial impact remains uncertain. Does Gilead Pairing With Nucleai Reveal a Deeper Shift in Its Oncology Strategy?
• Positive Sentiment: BMO Capital reaffirmed its Buy rating, reinforcing the view that Gilead’s HIV franchise, oncology investments and pipeline can support further gains. BMO Capital Reaffirms Buy Rating on Gilead Sciences
• Positive Sentiment: Zacks Research raised its FY2026 EPS forecast from a loss of $1.05 to a loss of $0.65 and increased its FY2027 estimate from $9.11 to $9.30. Several quarterly estimates for late 2026 and 2027 were also raised, suggesting improving expectations for future profitability.
• Neutral Sentiment: The recent rally extended to seven consecutive sessions, indicating strong momentum, but the subsequent consolidation may reflect profit-taking as the stock trades near its 52-week high. Gilead Rises for the Seventh Straight Session
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82, equivalent to $3.28 annually and a yield of roughly 2.3%. The payout supports income-oriented investors, though the reported negative payout ratio reflects currently distorted earnings.
• Negative Sentiment: Zacks lowered its FY2028 EPS forecast from $10.00 to $9.58 and cut estimates for Q1 and Q2 2028. Although several nearer-term estimates increased, the mixed revisions signal uncertainty around the longer-term earnings trajectory.
• Negative Sentiment: CFO Andrew Dickinson sold 3,000 shares for approximately $415,000. The transaction occurred under a pre-arranged Rule 10b5-1 plan and left him with substantial holdings, making it a limited bearish signal, but insider selling can weigh modestly on sentiment. Gilead Sciences CFO Sells 3,000 Shares

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $137.64, for a total value of $3,853,920.00. Following the completion of the sale, the insider owned 118,234 shares of the company's stock, valued at approximately $16,273,727.76. This represents a 19.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $138.36, for a total transaction of $415,080.00. Following the completion of the transaction, the chief financial officer directly owned 165,646 shares of the company's stock, valued at $22,918,780.56. This represents a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 82,000 shares of company stock valued at $10,837,860. Insiders own 0.30% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on GILD shares. Leerink Partners lowered Gilead Sciences from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $146.00 to $127.00 in a report on Tuesday, July 21st. Morgan Stanley dropped their price target on Gilead Sciences from $166.00 to $165.00 and set an "overweight" rating on the stock in a research report on Monday, July 27th. Wall Street Zen upgraded Gilead Sciences from a "hold" rating to a "buy" rating in a report on Saturday, August 15th. Needham & Company LLC reiterated a "buy" rating and issued a $170.00 price objective on shares of Gilead Sciences in a research report on Wednesday, August 5th. Finally, Truist Financial lowered their target price on Gilead Sciences from $157.00 to $156.00 and set a "buy" rating for the company in a research note on Tuesday, July 7th. Twenty-four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $158.04.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $143.44 on Friday. The stock's 50-day moving average is $131.56 and its 200-day moving average is $136.52. Gilead Sciences, Inc. has a one year low of $108.46 and a one year high of $157.29. The firm has a market cap of $177.86 billion, a price-to-earnings ratio of -53.72 and a beta of 0.32. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm had revenue of $7.80 billion for the quarter, compared to analysts' expectations of $7.40 billion. During the same quarter in the previous year, the business posted $2.01 EPS. The business's quarterly revenue was up 10.6% compared to the same quarter last year. Equities analysts predict that Gilead Sciences, Inc. will post -0.51 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a $0.82 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. Gilead Sciences's dividend payout ratio (DPR) is presently -122.85%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source